Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 1, 2007, Pages 149-164

  Rohde, Jeffrey J ^a   Pliushchev, Marina A ^a   Sorensen, Bryan K ^a   Wodka, Dariusz ^b   Shuai, Qi ^a   Wang, Jiahong ^a   Fung, Steven ^a   Monzon, Katina M ^a   Chiou, William J ^a   Pan, Liping ^c   Deng, Xiaoqing ^c   Chovan, Linda E ^b   Ramaiya, Atul ^c   Mullally, Mark ^b   Henry, Rodger F ^d   Stolarik, DeAnne F ^c   Imade, Hovis M ^c   Marsh, Kennan C ^c   Beno, David W A ^c   Fey, Thomas A ^a   Droz, Brian A ^a   Brune, Michael E ^a   Camp, Heidi S ^a   Sham, Hing L ^a   Frevert, Ernst Uli ^e   Jacobson, Peer B ^a   Link, J T ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b Medicinal Chemistry Technologies

^c Drug Metabolism ^*  (United States)

^d Structural Chemistry

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

11 BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 11BETA HYDROXYSTEROID DEHYDROGENASE; ADAMANTANE DERIVATIVE; ENZYME INHIBITOR; N (5 HYDROXY 2 ADAMANTYL) 2 [4 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL]PIPERAZIN 1 YL]ACETAMIDE; N (5 HYDROXY 2 ADAMANTYL) 2 [4 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL]PIPERAZIN 1 YL]PROPIONAMIDE; N ADAMANTAN 2 YL 2 [4 (3 CYANO PYRIDIN 2 YL)PIPERAZIN 1 YL]ACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADAMANTANE; ANIMALS; CELL LINE; HUMANS; MICE; MICROSOMES, LIVER; PIPERAZINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 33846228383     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0609364     Document Type: Article

References (91)

1. (a) Trevisan, M.; Liu, J.; Bahsas, F. B.; Menotti, A. Syndrome X and mortality: A population-based study. Risk factor and life expectancy research group. Am. J. Epidemiol. 1998, 148, 958-966.
2. (b) Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, M. R.; Groop, L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24, 683-689.
3. (c) Tomlinson, J. W.; Stewart, P. M. Mechanisms of disease: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat. Clin. Prac. Endocrinol. Metab. 2005, 1, 92-99.
4. (d) Wang, M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. 2005, 2, 1-14.
5. Alberti, K. G. M. M.; Zimmet, P.; Shaw, J. Metabolic syndrome - a new world definition. A consensus statement from the international diabetes federation. Diabetes Med. 2006, 23, 469-480.
6. Arnaldi, G.; Angeli, A.; Atkinson, A. B.; Bertagna, X.; Cavagnini, F.; Chrousos, G. P.; Fava, G. A.; Findling, J. W.; Gaillard, R. C.; Grossman, A. B.; Kola, B.; Lacroix, A.; Mancini, T.; Mantero, F.; Newell-Price, J.; Nieman, L. K.; Sonino, N.; Vance, M. L.; Giustina, A.; Boscaro, M. Diagnosis and complications of Cushing's syndrome: A consensus statement. J. Clin. Endocrinol. Metab. 2003, 88, 5593-5602.
7. (a) Watanabe, K.; Adachi, A.; Nakamura, R. Reversible panhypopituitarism due to Cushing's syndrome. Arch. Intern. Med. 1988, 148, 1358-1360.
8. (b) McEwen, B. S. Cortisol, Cushing's syndrome, and a shrinking brain - new evidence for reversibility. J. Clin. Endocrinol. Metab. 2002, 87, 1947-1948.
9. (c) Inagaki, K.; Otsuka, F.; Miyoshi, T.; Watanabe, N.; Suzuki, J.; Ogura, T.; Makino, H. Reversible pituitary dysfunction in a patient with Cushing's syndrome discovered as adrenal incidentaloma. Endocr. J. 2004, 51, 201-206.
10. Fraser, R.; Ingram, M. C.; Anderson, N. H.; Morrison, C.; Davies, E.; Connell, J. M. C. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33, 1364-1368.
11. (a) Seckl, J. R.; Walker, B. R. Minireview: 11β-Hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action. Endocrinology 2001, 142, 1371-1376.
12. (b) Tomlinson, J. W.; Walker, E. A.; Bujalska, I. J.; Draper, N.; Lavery, G. G.; Cooper, M. S.; Hewison, M.; Stewart, P. M. 11β-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25, 831-866.
13. (c) Wake, D. J.; Walker, B. R. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine 2006, 29, 101-108.
14. (a) Amelung, D.; Hubener, H. J.; Roka, L.; Meyerheim, G. Conversion of cortisone to compound F. J. Clin. Endocrinol. Metab. 1953, 13, 1125-1126.
15. (b) Lakshmi, V.; Monder, C. Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 1988, 123, 2390-2398.
16. (c) Edwards, C. R. W.; Stewart, P. M.; Burt, D.; Brett, L.; McIntyre, M. A.; Sutanto, W. S.; De Kloet, E. R.; Monder, C. Localization of 11β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2, 986-989.
17. (d) Funder, J. W.; Pearce, P. T.; Smith, R.; Smith, A. I. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242, 583-585.
18. (a) Agarwal, A. K.; Monder, C.; Eckstein, B.; White, P. C. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J. Biol. Chem. 1989, 264, 18939-18943.
19. (b) Monder, C.; White, P. C. 11β-Hydroxysteroid dehydrogenase. Vitam. Horm. 1993, 47, 187-271.
20. (c) Low, S. C.; Chapman, K. E.; Edwards, C. R. W.; Seckl, J. R. "Liver-type" 11β-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. J. Mol. Endocrinol. 1994, 13, 167-174.
21. (d) Bujalska, I. J.; Kumar, S.; Stewart, P. M. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997, 349, 1210-1213.
22. (e) Katz, J. R.; Mohamed-Ali, V.; Wood, P. J.; Yudkin, J. S.; Coppack, S. W. An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin. Endocrinol. 1999, 50, 63-68.
23. (f) Stewart. P. M.; Krozowski, Z. S. 11β-Hydroxysteroid dehydrogenase. Vitam. Horm. 1999, 37, 249-324.
24. (g) Jamieson, P. M.; Walker, B. R.; Chapman, K. E.; Andrew, R.; Rossiter, S.; Seckl, J. R. 11β-Hydroxysteroid dehydrogenase type 1 is a predominant 11β-reductase in the intact perfused rat liver. J. Endocrinol. 2000, 165, 685-692.
25. (a) Brown, R. W.; Chapman, K. E.; Edwards, C. R. W.; Seckl, J. R. Human placental 11β-hydroxysteroid dehydrogenase: Evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 1993, 132, 2614-2621.
26. (b) Albiston, A. L.; Obeyesekere, V. R.; Smith, R. E.; Krozowski, Z. S. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell Endocrinol. 1994, 105, R11-R17.
27. (c) Agarwal, A. K.; Mune, T.; Monder, C.; White, P. C. NAD+-dependent isoform of 11β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J. Biol. Chem. 1994, 209, 25959-25962.
28. Arriza, J. L.; Weinberger, C.; Cerelli, G.; Glase, T. M.; Handelin, B. L.; Housman, D. E.; Evans, R. M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237, 268-275.
29. (a) Mune, T.; Rogerson, F. M.; Nikkila, H.; Agarwal, A. K.; White, P. C. Human hypertension caused by mutations in the kidney isoenzyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet. 1995, 10, 394-399.
30. (b) Dave-Sharma, S.; Wilson, R. C.; Harbison, M. D.; Newfield, R.; Azar, M. R.; Krozowski, Z. S.; Funder, J. W.; Shackleton, C. H. L.; Bradlow, H. L.; Wei, J.-Q.; Hertecant, J.; Moran, A.; Neiberger, R. E.; Balfe, J. W.; Fattah, A.; Daneman, D.; Akkurt, H. I.; De Santis, C.; New, M. I. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1998, 83, 2244-2254.
31. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14924-14929.
32. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 2001, 276, 41293-41300.
33. (a) Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294, 2166-2170.
34. (b) Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G. F.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112, 83-90.
35. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7088-7093.
36. Kershaw, E. E.; Morton, N. M.; Dhillon, H.; Ramage, L.; Seckl, J. R.; Flier, J. S. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005, 54, 1023-1031.
37. Morton, N. M.; Ramage, L.; Seckl, J. R. Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: A potential adaptive mechanism counteracting metabolic disease. Endocrinology 2004, 145, 2707-2712.
38. (a) Rask, E.; Olsson, T.; Soderberg, S.; Andrew, R.; Livingstone, D. E. W.; Johnson, O.; Walker, B. R. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 2001, 86, 1418-1421.
39. (b) Paulmyer-Lacroix, O.; Boullu, S.; Oliver, C.; Alessi, M.-C.; Grino, M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: An in situ hybridization study. J. Clin. Endocrinol. Metab. 2002, 87, 2701-2705.
40. (c) Rask, E.; Walker, B. R.; Soderberg, S.; Livingstone, D. E. W.; Eliasson, M.; Johnson, O.; Andrew, R.; Olsson, T. Tissue-specific changes in peripheral cortisol metabolism in obese women: Increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 2002, 87, 3330-3336.
41. (d) Lindsay, R. S.; Wake, D. J.; Nair, S.; Bunt, J.; Livingstone, D. E. W.; Permana, P. A.; Tataranni, P. A.; Walker, B. R. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 2003, 88, 2738-2744.
42. (e) Wake, D. J.; Rask, E.; Livingstone, D. E. W.; Soederberg, S.; Olsson, T.; Walker, B. R. Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 2003, 88, 3983-3988.
43. (f) Engeli, S.; Boehnke, J.; Feldpausch, M.; Gorzelniak, K.; Heintze, U.; Janke, J.; Luft, F. C.; Sharma, A. M. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 2004, 12, 9-17.
44. (g) Kannisto, K.; Pietilaeinen, K. H.; Ehrenborg, E.; Rissanen, A.; Kaprio, J.; Hamsten, A.; Yki-Jaervinen, H. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: Studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 2004, 89, 4414-4421.
45. (h) Sandeep, T. C.; Andrew, R.; Homer, N. Z. M.; Andrews, R. C.; Smith, K.; Walker, B. R. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005, 54, 872-879.
46. Tomlinson, J. W.; Sinha, B.; Bujalska, I.; Hewison, M.; Stewart, P. M. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 2002, 87, 5630-5635.
47. Stewart, P. M.; Boulton, A.; Kumar, S.; Clark, P. M. S.; Shackleton, C. H. L. Cortisol metabolism in human obesity: Impaired cortisone→ cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 1999, 84, 1022-1027.
48. Purnell, J. Q.; Brandon, D. D.; Isabelle, L. M.; Loriaux, D. L.; Samuels, M. H. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J. Clin. Endocrinol. Metab. 2004, 89, 281-287.
49. (a) Andrew, R.; Smith, K.; Jones, G. C.; Walker, B. R. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J. Clin. Endocrinol. Metab. 2002, 87, 277-285.
50. (b) Basu, R.; Singh, R. J.; Basu, A.; Chittilapilly, E. G.; Johnson, C. M.; Toffolo, G.; Cobelli, C.; Rizza, R. A. Splanchnic cortisol production occurs in humans: Evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 2004, 53, 2051-2059.
51. (c) Andrew, R.; Westerbacka, J.; Wahren, J.; Yki-Jaervinen, H.; Walker, B. R. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005, 54, 1364-1370.
52. (d) Basu, R.; Singh, R. J.; Basu, A.; Chittilapilly, E. G.; Johnson, M. C.; Toffolo, G.; Cobelli, C.; Rizza, R. A. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J. Clin. Endocrinol. Metab. 2005, 90, 3919-3926.
53. (a) Chrousos, G. P. Is 11β-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6329-6330.
54. (b) Davies, E.; MacKenzie, S. M. Extra-adrenal production of corticosteroids. Clin. Exp. Pharmacol. Physiol. 2003, 30, 437-445.
55. (c) Giordano, R.; Pellegrino, M.; Picu, A.; Bonelli, L.; Balbo, M.; Berardelli, R.; Lanfranco, F.; Ghigo, E.; Arvat, E. Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: Effects of GABA-, mineralocorticoid-, and GH-secretagogue-receptor modulation. The-ScientificWorld 2006, 6, 1-11.
56. (d) Swaab, D. F.; Bao, A.-M.; Lucassen, P. J. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 2005, 4, 141-194.
57. (e) Buckley, T. M.; Schatzberg, A. F. Review. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: Normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 2005, 90, 3106-3114.
58. Human and rodent species differences in androgen metabolism and function are known. (a) Karsch, F. J.; Dierschke, D. J.; Knobil, E. Sexual differentiation of pituitary function: Apparent difference between primates and rodents. Science 1973, 179, 484-486.
59. (b) Grino, M. Adrenal cortex, development. Encycl. Endocr. Dis. 2004, 1, 53-60.
60. (c) Smith, C. J.; Norman, R. L. Circadian periodicity in circulating cortisol is absent after orchidectomy in rhesus macaques. Endocrinology 1987, 121, 2186-2191.
61. Harris, H. J.; Kotelevtsev, Y.; Mullins, J. J.; Seckl, J. R.; Holmes, M. C. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: Analysis of 11β-HSD-1-deficient mice. Endocrinology 2001, 142, 114-120.
62. Wang, M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr. Opin. Invest. Drugs 2006, 7, 319-323 and reference contained therein to Paterson, J. Studies of 11β-Hydroxysteroid dehydrogenase type 1 in transgenic mouse models. Glucocorticoid Activation as a Pharmacological Target in Metabolic Disease Conference, Stockholm, Sweden, 2005.
63. (a) Livingston, D. E. W.; Walker, B. R. Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exp. Ther. 2003, 305, 167-172.
64. (b) Andrews, R. C.; Rooyackers, O.; Walker, B. R. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88, 285-291.
65. (c) Sandeep, T. C.; Yau, J. L. W.; MacLullich, A. M. J.; Noble, J.; Deary, I. J.; Walker, B. R.; Seckl, J. R. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6734-6739.
66. (a) Barf, T.; Vallgarda, J; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45, 3813-3815.
67. (b) Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.; Larsson, C.; Ronquist-Nii, Y.; Ohman, B.; Abrahmsen, L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45, 1528-1532.
68. (c) Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O. M.; Edling, N. H. M.; Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L. B. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144, 4755-4762.
69. (a) Olson, S.; Aster, S. D.; Brown, K; Carbin, L.; Graham, D. W.; Hermanowski-Vosatka, A. H.; LiGrand, C. B.; Mundt, S. S.; Robbins, M. A.; Schaeffer, J. M.; Slossberg, L. H.; Szymonifka, M. J.; Thieringer, R.; Wright, S. D.; Balkovec, J. M. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359-4362.
70. (b) Hermanowski-Vosatka, A. H.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo. G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005, 202, 517-527.
71. Yau, J. L. W.; Noble, J.; Kenyon, C. J.; Hibberd, C.; Kotelevtsev, Y.; Mullins, J. J.; Seckl, J. R. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4716-4721.
72. Rauz, S.; Cheung, C. M. G.; Wood, P. J.; Coca-Prados, M.; Walker, E. A.; Murray, P. I.; Stewart, P. M. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension. QJM: Monthly Journal of the Association of Physicians 2003, 96, 481-490.
73. Cai, T.-Q.; Wong, B.; Mundt, S. S.; Thieringer, R.; Wright, S. D.; Hermanowski-Vosatka, A. Induction of 11β-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol. Biol. 2001, 77, 117-122.
74. Cooper, M. S.; Rabbitt, E. H.; Goddard, P. E.; Bartlett, W. A.; Hewison, M.; Stewart, P. M. Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 2002, 17, 979-986.
75. Nilsson, C.; Dreifeldt, C. Method for promoting impaired wound healing. PCT Int. Appl. WO2004112785, 2004.
76. Tomlinson, J. W. 11β-hydroxysteroid dehydrogenase type 1 in human disease: A novel therapeutic target. Minerva Endocrinol. 2005, 30, 37-46.
77. Espino, C. G.; Du Bois, J. A Rh-catalyzed C-H insertion reaction for the oxidative conversion of carbamates to oxazolidinones. Angew. Chem., Int. Ed. 2001, 40, 598-600.
78. Kocovsky, P. Carbamates: A method of synthesis and some synthetic applications. Tetrahedron Lett. 1986, 27, 5521-5524.
79. Jones, C. D.; Kaselj, M.; Salvatore, R. N.; le Noble, W. J. Effects of substituent modification on face selection in reduction. J. Org. Chem. 1998, 63, 2758-2760.
80. Fischer, W.; Grob, C. A.; Katayama, H. The synthesis of 1,3-disubstituted adamantanes. Helv. Chim. Acta 1976, 59, 1953-1962.
81. Jasys, V. J.; Lombardo, F.; Appleton, T. A.; Bordner, J.; Ziliox, M.; Volkmann, R. A. Preparation of fluoroadamantane acids and amines: Impact of bridgehead fluorine substitution on the solution-and solid-state properties of functionalized adamantanes. J. Am. Chem. Soc. 2000, 122, 466-473.
82. Bhatia, P. A.; Daanen, J. F.; Hakeem, A. A.; Kolasa, T.; Matulenko, M. A.; Mortell, K. H.; Patel, M. V.; Stewart, A. O.; Wang, X.; Xia, Z.; Zhang, H. Q. Preparation of piperazinyl, piperidinyl and related acetamides and benzamides as dopamine D4 receptor agonists useful in treating sexual dysfunction. U.S. Pat. Appl. Publ. US2003229094, 2003.
83. (a) Tsuzuki, N.; Hama, T.; Kawada, M.; Hasui, A.; Konishi, R.; Shiwa, S.; Ochi, Y.; Futaki, S.; Kitagawa, K. Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. J. Pharm Sci. 1994, 83, 481-484.
84. (b) Tsuzuki, N.; Hama, T.; Hibi, T.; Konishi, R.; Futaki, S.; Kitagawa, K. Adamantane as a brain-directed drug carrier for poorly absorbed drug: Antinociceptive effects of [D-Ala2]Leu-enkephalin derivatives conjugated with the 1-adamantane moiety. Biochem. Pharmacol. 1991, 41, R5-R8.
85. (c) Wishnok, J. S. Medicinal properties of adamantane derivatives. J. Chem. Educ. 1973, 50, 780-781.
86. (a) White, R. E.; McCarthy, M.-B.; Egeberg, K. D. Sugar, S. G. Regioselectivity in the cytochromes P-450: Control by protein constraints and by chemical reactivities. Arch. Biochem. Biophys. 1984, 228, 493-502.
87. CAM complexed with camphane, thiocamphor, and adamantane: Factors controlling P-450 substrate hydroxylation. Biochemistry 1991, 30, 2674-2684.
88. Receptor binding assays performed by CEREP (www.cerep.com).
89. Ziegler, F. E.; Fowler, K. W. Substitution reactions of specifically ortho-metalated piperonal cyclohexylimine. J. Org. Chem. 1976, 41, 1564-1566.
90. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27, 1350-1359.
91. Gao, L.; Chiou, W.; Cheng, X.; Camp, H.; Burns, D. Quantification Of corticosteroids from ex vivo activity assay. Proceedings of the 54th ASMS Conference on Mass Spectrometry, Seattle, WA, U.S.A., May 29-June 1, 2006.